{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:53:53Z","timestamp":1763348033026},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T00:00:00Z","timestamp":1456272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Prostate Cancer Foundation NZ","award":["07332"],"award-info":[{"award-number":["07332"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s11010-016-2671-8","type":"journal-article","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T08:38:05Z","timestamp":1456303085000},"page":"187-199","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Uric acid: a modulator of prostate cells and activin sensitivity"],"prefix":"10.1007","volume":"414","author":[{"given":"Febbie","family":"Sangkop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geeta","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ely","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elspeth","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Bahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,24]]},"reference":[{"key":"2671_CR1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/374354a0","volume":"374","author":"MM Matzuk","year":"1995","unstructured":"Matzuk MM, Kumar TR, Vassalli A, Bickenbach JR, Roop DR, Jaenisch R, Bradley A (1995) Functional analysis of activins during mammalian development. Nature 374:354\u2013356","journal-title":"Nature"},{"key":"2671_CR2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1210\/edrv.22.6.0450","volume":"22","author":"GP Risbridger","year":"2001","unstructured":"Risbridger GP, Schmitt JF, Robertson DM (2001) Activins and inhibins in endocrine and other tumors. Endocr Rev 22:836\u2013858","journal-title":"Endocr Rev"},{"key":"2671_CR3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/wdev.86","volume":"2","author":"A Weiss","year":"2013","unstructured":"Weiss A, Attisano L (2013) The TGF-beta superfamily signaling pathway. Wiley Interdiscip Rev Dev Biol 2:47\u201363","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"2671_CR4","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1126\/science.1071809","volume":"296","author":"L Attisano","year":"2002","unstructured":"Attisano L, Wrana JL (2002) Signal transduction by the TGF-\u03b2 superfamily. Science 296:1646\u20131647","journal-title":"Science"},{"key":"2671_CR5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/153537020623100507","volume":"231","author":"Y-G Chen","year":"2006","unstructured":"Chen Y-G, Wang Q, Lin S-L, Chang CD, Chung J, Ying S-Y (2006) Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis. Exp Biol Med 231:534\u2013544","journal-title":"Exp Biol Med"},{"key":"2671_CR6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/35043051","volume":"1","author":"J Massague","year":"2000","unstructured":"Massague J (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1:169\u2013178","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2671_CR7","first-page":"591","volume":"11","author":"S Ying","year":"1997","unstructured":"Ying S, Zhang Z, Batres Y, Zhao Y, Lin S, Li G (1997) p53 is involved in the inhibition of cell proliferation mediated by activin A in cultured human prostate cancer LNCaP cells. Int J Oncol 11:591\u2013595","journal-title":"Int J Oncol"},{"key":"2671_CR8","first-page":"1809","volume":"43","author":"JS Horoszewicz","year":"1983","unstructured":"Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43:1809\u20131818","journal-title":"Cancer Res"},{"key":"2671_CR9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1677\/joe.0.1540535","volume":"154","author":"S McPherson","year":"1997","unstructured":"McPherson S, Thomas T, Wang H, Gurusinghe C, Risbridger G (1997) Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145. J Endocrinol 154:535\u2013545","journal-title":"J Endocrinol"},{"key":"2671_CR10","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1210\/endo.137.12.8940339","volume":"137","author":"AC Dalkin","year":"1996","unstructured":"Dalkin AC, Gilrain JT, Bradshaw D, Myers CE (1996) Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells. Endocrinology 137:5230\u20135235","journal-title":"Endocrinology"},{"key":"2671_CR11","first-page":"16","volume":"17","author":"M Kaighn","year":"1979","unstructured":"Kaighn M, Narayan KS, Ohnuki Y, Lechner J, Jones L (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16\u201323","journal-title":"Invest Urol"},{"key":"2671_CR12","doi-asserted-by":"crossref","first-page":"16239","DOI":"10.1073\/pnas.0705971104","volume":"104","author":"KL Jones","year":"2007","unstructured":"Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, de Kretser DM, Phillips DJ (2007) Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci USA 104:16239\u201316244","journal-title":"Proc Natl Acad Sci USA"},{"key":"2671_CR13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neulet.2006.11.065","volume":"413","author":"S Ebert","year":"2007","unstructured":"Ebert S, Zeretzke M, Nau R, Michel U (2007) Microglial cells and peritoneal macrophages release activin A upon stimulation with Toll-like receptor agonists. Neurosci Lett 413:241\u2013244","journal-title":"Neurosci Lett"},{"key":"2671_CR14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cytogfr.2009.02.007","volume":"20","author":"DJ Phillips","year":"2009","unstructured":"Phillips DJ, de Kretser DM, Hedger MP (2009) Activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev 20:153\u2013164","journal-title":"Cytokine Growth Factor Rev"},{"key":"2671_CR15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1365-2249.1998.00522.x","volume":"112","author":"WE Yu","year":"1998","unstructured":"Yu WE, Dolter KE, Shao LE, Yu J (1998) Suppression of IL-6 biological activities by activin A and implications for inflammatory arthropathies. Clin Exp Immunol 112:126\u2013132","journal-title":"Clin Exp Immunol"},{"key":"2671_CR16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","volume":"375","author":"P Richette","year":"2010","unstructured":"Richette P, Bardin T (2010) Gout. Lancet 375:318\u2013328","journal-title":"Gout. Lancet"},{"key":"2671_CR17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ans.12042","volume":"83","author":"V Blair","year":"2013","unstructured":"Blair V, Kahokehr A, Sammour T (2013) Cancer in Maori: lessons from prostate, colorectal and gastric cancer and progress in hereditary stomach cancer in New Zealand. ANZ J Surg 83:42\u201348","journal-title":"ANZ J Surg"},{"key":"2671_CR18","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10552-008-9166-1","volume":"19","author":"MJ Sneyd","year":"2008","unstructured":"Sneyd MJ (2008) Ethnic differences in prostate cancer survival in New Zealand: a national study. Cancer Causes Control 19:993\u2013999","journal-title":"Cancer Causes Control"},{"key":"2671_CR19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.7150\/jca.8152","volume":"5","author":"R Lawrenson","year":"2014","unstructured":"Lawrenson R, Obertov\u00e1 Z, Brown C, Fong P, Tyrie L, Scott N, Holmes M (2014) The use of androgen deprivation therapy (ADT) and chemotherapeutic agents in New Zealand men with prostate cancer. J Cancer 5:214","journal-title":"J Cancer"},{"key":"2671_CR20","first-page":"14","volume":"112","author":"Z Obertova","year":"2013","unstructured":"Obertova Z, Scott N, Brown C, Stewart A, Lawernson R (2013) Survival disparities between M\u0101ori and non-M\u0101ori men with non-localised prostate cancer in New Zealand. BJU Int 112:14","journal-title":"BJU Int"},{"key":"2671_CR21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.molbev.a004123","volume":"19","author":"M Oda","year":"2002","unstructured":"Oda M, Satta Y, Takenaka O, Takahata N (2002) Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19:640\u2013653","journal-title":"Mol Biol Evol"},{"key":"2671_CR22","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2337\/db12-1814","volume":"62","author":"RJ Johnson","year":"2013","unstructured":"Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, Ishimoto T, Sautin YY, Lanaspa MA (2013) Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 62:3307\u20133315","journal-title":"Diabetes"},{"key":"2671_CR23","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1172\/JCI42344","volume":"120","author":"A So","year":"2010","unstructured":"So A, Thorens B (2010) Uric acid transport and disease. J Clin Investig 120:1791\u20131799. doi: 10.1172\/jci42344","journal-title":"J Clin Investig"},{"key":"2671_CR24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1681\/ASN.2006040415","volume":"18","author":"Y Hagos","year":"2007","unstructured":"Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A (2007) Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 18:430\u2013439","journal-title":"J Am Soc Nephrol"},{"key":"2671_CR25","doi-asserted-by":"crossref","first-page":"15501","DOI":"10.1073\/pnas.0904411106","volume":"106","author":"F Preitner","year":"2009","unstructured":"Preitner F, Bonny O, Laverri\u00e8re A, Rotman S, Firsov D, Da Costa A, Metref S, Thorens B (2009) Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci 106:15501\u201315506","journal-title":"Proc Natl Acad Sci"},{"key":"2671_CR26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10157-005-0368-5","volume":"9","author":"A Enomoto","year":"2005","unstructured":"Enomoto A, Endou H (2005) Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol 9:195\u2013205","journal-title":"Clin Exp Nephrol"},{"key":"2671_CR27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/scrt343","volume":"4","author":"KJ Gangavarapu","year":"2013","unstructured":"Gangavarapu KJ, Azabdaftari G, Morrison CD, Miller A, Foster BA, Huss WJ (2013) Aldehyde dehydrogenase and ATP binding cassette transporter G2 (ABCG2) functional assays isolate different populations of prostate stem cells where ABCG2 function selects for cells with increased stem cell activity. Stem Cell Res Ther 4:132","journal-title":"Stem Cell Res Ther"},{"key":"2671_CR28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tips.2008.01.006","volume":"29","author":"FG Russel","year":"2008","unstructured":"Russel FG, Koenderink JB, Masereeuw R (2008) Multidrug resistance protein 4 (MRP4\/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci 29:200\u2013207","journal-title":"Trends Pharmacol Sci"},{"key":"2671_CR29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ng.106","volume":"40","author":"V Vitart","year":"2008","unstructured":"Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J (2008) SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 40:437\u2013442","journal-title":"Nat Genet"},{"key":"2671_CR30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11926-012-0240-z","volume":"14","author":"MS Lipkowitz","year":"2012","unstructured":"Lipkowitz MS (2012) Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep 14:179\u2013188","journal-title":"Curr Rheumatol Rep"},{"key":"2671_CR31","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/15257770.2011.633953","volume":"30","author":"A Nakayama","year":"2011","unstructured":"Nakayama A, Matsuo H, Takada T, Ichida K, Nakamura T, Ikebuchi Y, Ito K, Hosoya T, Kanai Y, Suzuki H (2011) ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans. Nucleosides Nucleotides Nucleic Acids 30:1091\u20131097","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"2671_CR32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ng.2500","volume":"45","author":"A K\u00f6ttgen","year":"2012","unstructured":"K\u00f6ttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, Pistis G, Ruggiero D, O\u2019Seaghdha CM, Haller T (2012) Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 45:145\u2013154","journal-title":"Nat Genet"},{"key":"2671_CR33","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1210\/jcem.82.11.4374","volume":"82","author":"TZ Thomas","year":"1997","unstructured":"Thomas TZ, Wang H, Niclasen P, O\u2019Bryan MK, Evans LW, Groome NP, Pedersen J, Risbridger GP (1997) Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer. J Clin Endocrinol Metab 82:3851\u20133858","journal-title":"J Clin Endocrinol Metab"},{"key":"2671_CR34","first-page":"4851","volume":"85","author":"SL Mellor","year":"2000","unstructured":"Mellor SL, Cranfield M, Ries R, Pedersen J, Cancilla B, de Kretser D, Groome NP, Mason AJ, Risbridger GP (2000) Localization of activin \u03b2A-, \u03b2B-, and \u03b2C-Subunits in human prostate and evidence for formation of new activin heterodimers of \u03b2 C-subunit. J Clin Endocrinol Metab 85:4851\u20134858","journal-title":"J Clin Endocrinol Metab"},{"key":"2671_CR35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10585-006-9010-5","volume":"23","author":"G Leto","year":"2006","unstructured":"Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, Rini G (2006) Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 23:117\u2013122","journal-title":"Clin Exp Metastasis"},{"key":"2671_CR36","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/j.juro.2012.10.071","volume":"189","author":"MNL St\u00f6lting","year":"2013","unstructured":"St\u00f6lting MNL, Ferrari S, Handschin C, Becskei A, Provenzano M, Sulser T, Eberli D (2013) Myoblasts inhibit prostate cancer growth by paracrine secretion of tumor necrosis factor-\u03b1. J Urol 189:1952\u20131959","journal-title":"J Urol"},{"key":"2671_CR37","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/pros.20809","volume":"68","author":"LL Ho","year":"2008","unstructured":"Ho LL, Kench JG, Handelsman DJ, Scheffer GL, Stricker PD, Grygiel JG, Sutherland RL, Henshall SM, Allen JD, Horvath LG (2008) Androgen regulation of multidrug resistance-associated protein 4 (MRP4\/ABCC4) in prostate cancer. Prostate 68:1421\u20131429","journal-title":"Prostate"},{"key":"2671_CR38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/(SICI)1097-4652(199909)180:3<431::AID-JCP14>3.0.CO;2-O","volume":"180","author":"G Singh","year":"1999","unstructured":"Singh G, Lakkis CL, Laucirica R, Epner DE (1999) Regulation of prostate cancer cell division by glucose. J Cell Physiol 180:431\u2013438","journal-title":"J Cell Physiol"},{"key":"2671_CR39","doi-asserted-by":"crossref","first-page":"F327","DOI":"10.1152\/ajprenal.00133.2004","volume":"288","author":"RA Aubel Van","year":"2005","unstructured":"Van Aubel RA, Smeets PH, van den Heuvel JJ, Russel FG (2005) Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 288:F327\u2013F333","journal-title":"Am J Physiol Renal Physiol"},{"key":"2671_CR40","doi-asserted-by":"crossref","first-page":"10338","DOI":"10.1073\/pnas.0901249106","volume":"106","author":"OM Woodward","year":"2009","unstructured":"Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M (2009) Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci USA 106:10338\u201310342","journal-title":"Proc Natl Acad Sci USA"},{"key":"2671_CR41","first-page":"119","volume":"26","author":"Y Itahana","year":"2014","unstructured":"Itahana Y, Han R, Barbier S, Lei Z, Rozen S, Itahana K (2014) The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense. Oncogene 26:119","journal-title":"Oncogene"},{"key":"2671_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2001-1326-1-1","volume":"1","author":"MA Fini","year":"2012","unstructured":"Fini MA, Elias A, Johnson RJ, Wright RM (2012) Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med 1:1\u201315","journal-title":"Clin Transl Med"},{"key":"2671_CR43","first-page":"14","volume":"21","author":"KO Rove","year":"2014","unstructured":"Rove KO, Crawford ED (2014) Traditional androgen ablation approaches to advanced prostate cancer: new insights. Can J Urol 21:14\u201321","journal-title":"Can J Urol"},{"key":"2671_CR44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11010-012-1455-z","volume":"372","author":"M Brys","year":"2013","unstructured":"Brys M, Morel A, Forma E, Krzeslak A, Wilkosz J, Rozanski W, Olas B (2013) Relationship of urinary isoprostanes to prostate cancer occurrence. Mol Cell Biochem 372:149\u2013153","journal-title":"Mol Cell Biochem"},{"key":"2671_CR45","first-page":"3","volume":"3","author":"G Perletti","year":"2010","unstructured":"Perletti G, Montanari E, Vral A, Gazzano G, Marras E, Mione S, Magri V (2010) Inflammation, prostatitis, proliferative inflammatory atrophy: \u2018fertile ground\u2019 for prostate cancer development? Mol Med Rep 3:3\u201312","journal-title":"Mol Med Rep"},{"key":"2671_CR46","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10552-014-0408-0","volume":"25","author":"N Taghizadeh","year":"2014","unstructured":"Taghizadeh N, Vonk JM, Boezen HM (2014) Serum uric acid levels and cancer mortality risk among males in a large general population-based cohort study. Cancer Causes Control 25:1075\u20131080","journal-title":"Cancer Causes Control"},{"key":"2671_CR47","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.juro.2007.05.145","volume":"178","author":"O Yossepowitch","year":"2007","unstructured":"Yossepowitch O, Pinchuk I, Gur U, Neumann A, Lichtenberg D, Baniel J (2007) Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol 178:1238\u20131243","journal-title":"J Urol"},{"key":"2671_CR48","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1158\/1535-7163.MCT-08-0539","volume":"7","author":"M Okabe","year":"2008","unstructured":"Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, Gottesman MM (2008) Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7:3081\u20133091","journal-title":"Mol Cancer Ther"},{"key":"2671_CR49","first-page":"164","volume":"1835","author":"L Szablewski","year":"2013","unstructured":"Szablewski L (2013) Expression of glucose transporters in cancers. Biochim Biophys Acta 1835:164\u2013169","journal-title":"Biochim Biophys Acta"},{"key":"2671_CR50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jbspin.2010.02.027","volume":"78","author":"TR Merriman","year":"2011","unstructured":"Merriman TR, Dalbeth N (2011) The genetic basis of hyperuricaemia and gout. Joint Bone Spine 78:35\u201340","journal-title":"Joint Bone Spine"},{"key":"2671_CR51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","volume":"136","author":"G Burckhardt","year":"2012","unstructured":"Burckhardt G (2012) Drug transport by organic anion transporters (OATs). Pharmacol Ther 136:106\u2013130","journal-title":"Pharmacol Ther"},{"key":"2671_CR52","first-page":"E141","volume":"298","author":"B Thorens","year":"2010","unstructured":"Thorens B, Mueckler M (2010) Glucose transporters in the 21st Century. Am J Physiol 298:E141\u2013E145","journal-title":"Am J Physiol"},{"key":"2671_CR53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/09687680110090456","volume":"18","author":"H-G Thorens","year":"2001","unstructured":"Thorens H-G, Bernard J (2001) The extended GLUT-family of sugar\/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members. Mol Membr Biol 18:247\u2013256","journal-title":"Mol Membr Biol"},{"key":"2671_CR54","doi-asserted-by":"crossref","first-page":"26834","DOI":"10.1074\/jbc.C800156200","volume":"283","author":"N Anzai","year":"2008","unstructured":"Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, Sakurai H (2008) Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 283:26834\u201326838","journal-title":"J Biol Chem"},{"key":"2671_CR55","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/epirev\/mxm006","volume":"29","author":"SJ Freedland","year":"2007","unstructured":"Freedland SJ, Platz EA (2007) Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29:88\u201397","journal-title":"Epidemiol Rev"},{"key":"2671_CR56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1055-9965.EPI-05-0614","volume":"15","author":"C Rodriguez","year":"2006","unstructured":"Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, Chao A, Patel AV, Thun MJ, Calle EE (2006) Meat consumption among Black and White men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomark Prev 15:211\u2013216","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2671_CR57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/oxfordjournals.epirev.a000798","volume":"23","author":"LN Kolonel","year":"2001","unstructured":"Kolonel LN (2001) Fat, meat, and prostate cancer. Epidemiol Rev 23:72\u201381","journal-title":"Epidemiol Rev"},{"key":"2671_CR58","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/jnci\/85.19.1571","volume":"85","author":"E Giovannucci","year":"1993","unstructured":"Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WC (1993) A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85:1571\u20131579","journal-title":"J Natl Cancer Inst"},{"key":"2671_CR59","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.eururo.2007.04.069","volume":"52","author":"WC Buschemeyer III","year":"2007","unstructured":"Buschemeyer WC III, Freedland SJ (2007) Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 52:331\u2013343","journal-title":"Eur Urol"},{"key":"2671_CR60","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ijo.2012.28","volume":"37","author":"C Dani","year":"2013","unstructured":"Dani C (2013) Activins in adipogenesis and obesity. Int J Obesity 37:163\u2013166","journal-title":"Int J Obesity"},{"key":"2671_CR61","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1136\/annrheumdis-2012-202732","volume":"72","author":"N Dalbeth","year":"2013","unstructured":"Dalbeth N, House ME, Gamble GD, Horne A, Pool B, Purvis L, Stewart A, Merriman M, Cadzow M, Phipps-Green A, Merriman TR (2013) Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load. Ann Rheum Dis 72:1868\u20131873","journal-title":"Ann Rheum Dis"},{"key":"2671_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-014-0409-8","volume":"16","author":"SL Kolasinski","year":"2014","unstructured":"Kolasinski SL (2014) Food, drink, and herbs: alternative therapies and gout. Curr Rheumatol Rep 16:1\u20137","journal-title":"Curr Rheumatol Rep"},{"key":"2671_CR63","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/ard.59.7.539","volume":"59","author":"P Dessein","year":"2000","unstructured":"Dessein P, Shipton E, Stanwix A, Joffe B, Ramokgadi J (2000) Beneficial effects of weight loss associated with moderate calorie\/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 59:539\u2013543","journal-title":"Ann Rheum Dis"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-016-2671-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11010-016-2671-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-016-2671-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T14:05:20Z","timestamp":1589637920000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11010-016-2671-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,24]]},"references-count":63,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["2671"],"URL":"https:\/\/doi.org\/10.1007\/s11010-016-2671-8","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,24]]}}}